Shares of Monte Rosa TherapeuticsGLUE surged to a nearly four-year high Tuesday after the biotech company said all four ...

Prostate cancer remains a significant public health problem. The current approach with prostate-specific antigen (PSA)-based screening has questionable effects on prostate cancer–specific mortality ...

The use of prostate-specific antigen (PSA) testing for prostate cancer screening remains the subject of scientific debate. Experts are unable to agree on how to balance the benefit of such testing ...

In late March 2020, my pregnant daughter-in-law and I compared health issues. Hot flashes? Check. Acidity? Yes. Sore breasts? That, too. Brain fog? You bet. Fatigue? Insomnia? Thinning hair? We both ...

Prostate cancer is the most common cancer in men in both the UK and the USA. Although prostate cancer mortality has fallen due to prostate-specific antigen testing and improvements in therapeutic ...

The U.S. Food and Drug Administration (FDA) has approved niraparib (Zejula) plus Akeega (abiraterone acetate) and prednisone ...

PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA ...

Francis Medical designed its Vanquish system with needle guidance and hands-free stabilization for vapor ablation of the ...

Observational data suggested that men with nonmetastatic prostate cancer lived longer if they followed a healthier lifestyle. A higher prostate cancer behavior score was associated with reductions in ...

Screening men for prostate cancer would save thousands of lives by slashing their risk of dying from the disease by 13 per cent, a major study reveals. Testing led to a ‘sustained reduction’ in deaths ...

Three-dimensional ultrasound-based spectroscopic imaging for the detection of prostate cancer. Background: We previously reported that physical activity may reduce prostate cancer (CaP) risk among men ...